Influence of glucagon replacement on the hyperglycemic and hyperketonemic response to prolonged somatostatin infusion in normal man. 1977

R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig

Somatostatin was infused for 6 h into seven normal subjects with and without a replacement dose of glucagon. The addition of glucagon to somatostatin resulted in a 30-40% rise in plasma glucagon, whereas plasma insulin declined by 40-50% in both treatment groups. Plasma glucose and glucose production initially increased 2-fold with glucagon replacement, and subsequently declined by 2-3 h to levels comparable to those observed with somatostatin alone. After 6 h plasma glucose and glucose kinetics were no different whether or not glucagon was present. The rise in blood ketones after somatostatin was not exaggerated by glucagon replacement. We conclude that glucagon lack is not a modifying factor in the late hyperglycemic and hyperketonemic response to prolonged infusions of somatostatin.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007659 Ketones Organic compounds containing a carbonyl group Ketone
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006943 Hyperglycemia Abnormally high BLOOD GLUCOSE level. Postprandial Hyperglycemia,Hyperglycemia, Postprandial,Hyperglycemias,Hyperglycemias, Postprandial,Postprandial Hyperglycemias
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
October 1983, Diabetes,
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
March 1984, The Journal of clinical endocrinology and metabolism,
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
September 1984, Clinical endocrinology,
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
October 1980, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
January 1954, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
January 1986, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition,
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
January 1990, Acta diabetologica latina,
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
September 1979, The Journal of pharmacology and experimental therapeutics,
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
October 1978, Diabetes,
R S Sherwin, and W Tamborlane, and R Hendler, and L Saccá, and R A DeFronzo, and P Felig
August 1977, Diabetologia,
Copied contents to your clipboard!